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Abstract
Background. Mortality rates of critically ill patients
with acute renal failure (ARF) requiring renal replace-
ment therapy (RRT) are high. Intermittent and
continuous RRT are available for these patients on
the intensive care units (ICUs). It is unknown which
technique is superior with respect to patient outcome.
Methods. We randomized 125 patients to treatment
with either continuous venovenous haemodiaﬁltration
(CVVHDF) or intermittent haemodialysis (IHD) from
a total of 191 patients with ARF in a tertiary-care
university hospital ICU. The primary end-point was
ICU and in-hospital mortality, while recovery of renal
function and hospital length of stay were secondary
end-points.
Results. During 30 months, no patient escaped ran-
domization for medical reasons. Sixty-six patients
were not randomized for non-medical reasons.
Of the 125 randomized patients, 70 were treated with
CVVHDF and 55 with IHD. The two groups were
comparable at the start of RRT with respect to age
(62±15 vs 62±15 years, CVVHDF vs IHD), gender
(66 vs 73% male sex), number of failed organ systems
(2.4±1.5 vs 2.5±1.6), Simpliﬁed Acute Physiology
Scores (57±17 vs 58±23), septicaemia (43 vs 51%),
shock (59 vs 58%) or previous surgery (53 vs 45%).
Mortality rates in the hospital (47 vs 51%, CVVHDF
vs IHD, P¼ 0.72) or in the ICU (34 vs 38%, P¼ 0.71)
were independent of the technique of RRT applied.
Hospital length of stay in the survivors was compa-
rable in patients on CVVHDF [median (range) 20
(6–71) days, n¼ 36] and in those on IHD [30 (2–89)
days, n¼ 27, P¼ 0.25]. The duration of RRT required
was the same in both groups.
Conclusion. The present investigation provides no
evidence for a survival beneﬁt of continuous vs
intermittent RRT in ICU patients with ARF.
Keywords: acute renal failure; haemodiaﬁltration;
haemodialysis; organ failure; randomized clinical trial
Introduction
Before new drugs are introduced onto the market,
an array of prerequisites have to be fulﬁlled including
prospective controlled trials comparing the efﬁcacy
of the new xenobiotic with that of the traditionally
prescribed drug. Interestingly, legal obligations appear
to be far less demanding when new therapeutic inter-
ventions other than pharmacotherapeutic agents are
marketed. This liberal attitude towards innovation in
the ﬁeld of therapeutic devices probably best explains
why the worldwide standard for renal replacement
therapy (RRT) in patients with acute renal failure,
intermittent haemodialysis (IHD), has not been com-
pared with the later developed continuous RRT [1]
in prospective controlled trials focusing on ﬁnal
therapeutic objectives, such as patient survival, length
of hospital stay or recovery of renal function in
patients with acute renal failure (ARF) until recently.
Mehta et al. [2] reported on a multicentre trial
performed between 1991 and 1995 in southern
California. In that trial, after exclusion of 208 patients
mainly for haemodynamic reasons or refusal of the
treating physician to include a given patient in the
study, 166 patients were randomized to either IHD or
continuous arteriovenous haemodiaﬁltration during
the ﬁrst 2 years of the trial or to continuous venovenous
haemodiaﬁltration (CVVHDF) for the rest of the
study period. As indicated by the authors, there were
signiﬁcant differences between the groups in several
covariates independently associated with mortality,
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including gender, hepatic failure and severity of illness
scores, in each instance biased in favour of the
intermittent dialysis group [2]. Thus, the observation
of the continuous therapy-associated increase in
intensive care unit (ICU) and in-hospital mortality
relative to IHD was difﬁcult to interpret. In addition,
most probably due to the multicentre approach, no
uniform strategy for clinical decisions, including timing
of initiation of dialysis or nutrition or haemodynamic
support, was possible.
To test the hypothesis that CVVHD reduces
in-hospital mortality, length of hospital stay or
recovery of renal function, when compared with IHD,
we performed a randomized controlled trial comparing
IHD with CVVHDF in the ICU in a single centre. The
single-centre approach was chosen for the following
reasons: (i) to minimize a randomization bias; (ii) to
avoid exclusion of patients from randomization for
medical reasons; (iii) to ensure a constant dialysis
approach during the study; and (iv) to control other
clinical decisions, such as timing of initiation and dose
of dialysis, nutrition and haemodynamic support.
Patients and methods
Patients
All patients admitted to the ICUs at the University Hospital
of Berne, who were scheduled for RRT for ARF as deﬁned
by serum creatinine levels >350 mmol/l (>4.0mg/dl) and/or
urine output <20ml/h between June 1998 and December
2000, were screened for this study. Patients with pre-existing
chronic renal failure (CRF) treated by RRT or patients
who needed a speciﬁc RRT for intoxication were excluded
from this study.
All screened patients were randomized immediately
before the need for RRT except for the following logistic
situations: (i) all CVVHDF machines were in use at the
time of randomization; and (ii) the patients were hospitalized
in the one out of the ﬁve ICU wards that did not have
the staff trained for CVVHDF. Non-randomized patients
were treated by IHD and were excluded from further
analyses.
Baseline vital signs, haemodynamic and laboratory data
were recorded for the ﬁrst ICU day and every day from the
time of nephrology consultation. Simpliﬁed Acute Physiology
Scores (SAPS) were computed at admission to the ICU to
assess the severity of the illness [3]. The number of organ
system failures was based on the criteria described by
Metha et al. [2]. Patients were randomized to IHD or
CVVHDF by a computer random number generator using
a ‘biased coin randomization’ procedure [4]. This procedure
was chosen since a restricted number of CVVHDF devices,
but an unrestricted number of machines for IHD, were
available. When two CVVHDF devices were available, the
probability was 2:1 in favour of CVVHDF and when only one
CVVHDF device was available, randomization was 2:1 in
favour of IHD. When all CVVHDF devices were engaged,
no randomization occurred. The study was approved by
the ethics committee of the University of Berne in 1995.
At that time, intermittent or continuous RRT for ARF was
used at our institution depending on the availability of the
devices and on personal preference because no evidence for
the superiority of one of the two methods was available [1].
Furthermore, no additional clinical data were recorded or
blood samples taken for this study. Therefore, it was agreed
with the ethics committee that no informed consent needed
to be asked for in participants in this study.
Once randomized, patients continued treatment with the
assigned form of RRT until discharge from the ICU, when all
patients still requiring RRT were switched to IHD. No
crossover from one to the other form of RRT was allowed
during the stay. The possibility of such a crossover would
have (i) invalidated the basic concept of this study that each
patient could be randomized (see above); and (ii) compro-
mised the interpretation of the outcome results [2]. None of
the patients was actually switched from one to the other form
of RRT treatment during the study.
A sample size of 100 patients per group was estimated to
allow the detection of a mortality difference of 20% between
the two groups with a power of 90% assuming an overall
mortality of 75% [5]. The same sample size would still
have provided a sufﬁcient power of 80% with a substantially
lower overall mortality of 50% [5]. The investigation was
terminated prematurely after 30 months when it became
increasingly more difﬁcult to guarantee that no patient
escaped randomization for medical reasons. No intermediate
data analysis was done prior to the end of the study.
Renal replacement techniques
Vascular access was obtained in all patients by insertion of
a Mahurkar double-lumen haemodialysis catheter (Sherwood
Medical Company, St Louis, MO) into the subclavian,
internal jugular or femoral vein by standard Seldinger
technique. Biocompatible polysulfone membranes were used
in IHD while acetonitrile membranes (AN69) were used in
CVVHDF. Daily supplements of trace elements and vitamins
or additional potassium chloride and sodium-hydrogen
phosphate were given as required. Also, supplemental
bicarbonate was administered during the study period when
necessary.
CVVHDF
CVVHDF was performed with the HOSPAL-Prisma device
(Gambro Healthcare, Lakewood, CO) using the proprietary
sets, including standard tubing and AN69 high-ﬂux haemo-
ﬁlters. The ﬁlter was initially rinsed with 1 l of normal saline
including 5000 IU of heparin for at least 30min. The system
was then connected to the patient. Either a loading dose of
1500 IU of heparin followed by an individual patient-adjusted
anticoagulation regimen or no anticoagulation was used.
Blood ﬂow ranged from 100 to 180ml/min. A standard
lactate-buffered ﬂuid was used as dialysate and substituate at
a combined rate of 2000ml/h. Fluids were rewarmed to 37C
by a heating device when appropriate, and pre-dilution was
used for ﬂuid substitution. This procedure yields urea and
creatinine clearances of 30ml/min.
IHD
IHD was performed using a standard haemodialysis device
(MiroClav, Baxter GmbH, Germany) and standard blood
lines. A high-ﬂux polysulfone haemodialysis ﬁlter (Fresenius
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GmbH, Bad Homburg, Germany) was used, starting the ﬁrst
session with a small surface area ﬁlter (F50) and increasing the
ﬁlter size (F60 or F80) on further sessions. Initial heparin
rinsing and circuit anticoagulation did not differ from
CVVHDF. Blood ﬂow ranged from 150 to 350ml/min.
A bicarbonate-buffered dialysate was used during IHD.
Ultraﬁltration rate was 250–1000ml/h to achieve a negative
ﬂuid balance that approximately matched the ﬂuid intake
minus estimated ﬂuids lost by other routes. In addition to
ﬂuid balance considerations, the frequency and duration of
IHD sessions were determined by taking into account
electrolyte or acid–base disturbances and an estimate of the
catabolic state. The usual IHD session lasted from 3 to 4 h.
This procedure yields urea and creatinine clearances of
slightly less than 200ml/min.
End-points and other variables
All-cause mortality in the ICU and in the hospital was the
primary end-point of the trial. Secondary end-points were
ﬂuid and nutritional needs, vasopressor requirement and
haemodynamic stability, control of azotaemia and volume
overload, ICU and hospital days, and renal function
recovery.
Blood pressure data on the ICU were recorded daily, and
for each day the minimum and maximum diastolic, systolic
and mean blood pressure were analysed. For each patient, the
average mean arterial pressure (MAP) throughout the period
on the ICU was calculated. Circulatory failure was deﬁned as
an average MAP 65mmHg during the entire ICU period.
The difference between daily maximum and minimum MAP
was used to analyse haemodynamic stability, which was
deﬁned as an average cumulative daily variability of MAP
<30mmHg.
For the analysis of vasopressor requirement, nutritional
needs and ﬂuid balance, the type and rate of substances
administered were analysed for differences in the two groups
according to (i) the number of patients for each variable;
(ii) the number of patient-days of treatment; and (iii) the
average dose or volume of substances received per 12 h
computed for the days they were given.
Renal function recovery in survivors was assessed by serum
creatinine values at discharge. Since some of the patients had
pre-existing CRF at inclusion, deﬁned as a stable increase
in serum creatinine >150 mmol/l at least 3 months prior to
randomization, full recovery was considered when baseline
creatinine values ±10% were reached.
Statistical analysis
Between-group differences for continuous variables were
analysed by the non-parametric Wilcoxon–Mann–Whitney
test and by analysis of variance (ANOVA). Categorical
variables were analysed by Fisher’s exact test. A multiple
logistic regression analysis was used to adjust for binary
end-points. Analyses were performed with the SYSTAT
9.0 software (SPSS, Chicago, IL). All statistical tests
were two-sided. Results are given as means±SD or median
and range.
Results
Study participants and randomization
During the 30 months of the trial, a total of 191 patients
were scheduled for RRT because of ARF (Figure 1).
Sixty-two patients (32%) were not randomized for the
logistic reasons described in Patients and methods. No
patient escaped randomization for medical reasons or
refusal to be randomized. Four patients were excluded
immediately after therapy was instituted for violation
of the randomization procedure.
Figure 1 shows the breakdown of all randomized
patients qualifying for RRT. Of the 125 randomized
191 ICU patients with
ARF requiring RRT
62 patients not
randomized
(non medical reasons)
129 patients randomized
(Biased coin randomization)
125 patients correctly
randomized
70 patients
CVVHDF
55 patients
IHD
4 patients with violation of the
randomization protocol
Fig. 1. Trial proﬁle and distribution of randomized patients.
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patients, 70 were treated with CVVDHF and 55 with
IHD. No patient was lost from the trial because of
incomplete follow-up. Table 1 compares the baseline
clinical characteristics of the two treatment groups.
There were no between-group differences with respect
to key variables. Of the 62 surgical patients, 36 under-
went cardiovascular surgery (CVVHDF vs IHD,
26 vs 10), 20 abdominal surgery (CVVHDF vs IHD,
8 vs 12) and 6 other surgeries (3 in each group). In
the non-surgical patient group, there were 17 patients
with heart diseases (CVVHDF vs IHD, 11 vs 6), 16
with respiratory diseases (CVVHDF vs IHD, 7 vs 9),
9 with malignancy (CVVHDF vs IHD, 5 vs 4) and
21 with miscellaneous disorders (CVVHDF vs IHD,
10 vs 11).
ICU and in-hospital mortality, co-morbid
conditions and severity of illness
The overall ICU and in-hospital mortalities for
both treatments were 36 and 49%, respectively. ICU
mortality was similar in patients treated with
CVVHDF and IHD [34 vs 38%, odds ratio (OR)
1.16, P¼ 0.71]. Similarly, in-hospital mortality was
not different between patients treated with CVVHD
(47%) and those treated with IHD (51%, OR 1.18,
P¼ 0.72). Male gender, age, presence or absence of
antecedent surgical procedures or liver failure were
not associated with an increased ICU (results not
given) and in-hospital mortality (Table 2). Pre-existing
CRF, deﬁned as a serum creatinine >150 mmol/l at
least 3 months before admission, tended to predict
an increased mortality. When patients were stratiﬁed
into tertiles based on their SAPS scores at the time of
admission to the ICU, overall mortality was directly
related to the degree of severity of illness. The number
of organs failing did not predict mortality (Table 2).
The presence of shock and treatment with catechol-
amines were strong predictors of mortality (Table 2).
Retrospective chart analysis of the 62 patients who
could not be randomized for logistic reasons and who
were treated by IHD revealed that 21 patients (34%)
died during the course of hospitalization. The tendency
for a slightly lower mortality in the non-randomized
patients compared with the randomized patients did
not reach statistical signiﬁcance (P¼ 0.14).
Fluids and nutrition
In total, there were 965 RRT treatment days on the
ICU (CVVHDF 510 days, IHD 455 days) (Table 3).
The type and rate of ﬂuids and nutrition administered
were analysed for differences between the two groups
according to the number of patients for each variable,
the number of patient-days of treatment and the
average dose or volume of substances received, com-
puted for the days they were administered (Table 3).
Table 2. Continuous (CVVHDF) vs intermittent (IHD) renal
replacement therapy for acute renal failure: prediction of
in-hospital mortality
Variable Parameter n %
mortality
OR P-value
RRT group CVVHDF 70 47.1 1.00 –
IHD 55 50.9 1.16 0.36
Gender Male 86 45.3 1.00 –
Female 39 53.8 1.41 0.39
Pre-existing CRF No 98 44.9 1.00 –
Yes 27 63.0 2.09 0.45
Age <60 40 47.5 1.00 –
60–70 41 51.2 1.16 0.82
>70 44 45.5 0.92 1.00
No. of organs failing 1–2 55 43.6 1.00 –
3 34 50.0 1.29 0.66
4 36 52.7 1.44 0.52
Liver failure No 93 47.3 1.00 –
Yes 32 50.0 1.11 0.41
SAPS <50 48 35.4 1.00 –
50–70 44 52.3 1.99 0.14
>70 33 60.6 2.81 0.04
Surgical No 63 41.3 1.00 –
Yes 62 56.7 1.75 0.15
Sepsis No 66 40.9 1.00 –
Yes 60 55.0 1.73 0.15
Shock No 51 37.2 1.00 –
Yes 74 55.4 2.09 0.07
Catecholamines No 30 23.3 1.00 –
Yes 95 56.8 4.3 0.002
OR¼odds ratio; CRF¼ chronic renal failure (serum creatinine
>150mmol/l).
Table 1. Characteristics of patients assigned to continuous
(CVVHDF) or intermittent (IHD) renal replacement therapy for
acute renal failure
Characteristics CVVHDF
(n¼ 70)
IHD (n¼ 55) P-value
Patients’ demographics
Age (years) 67 (19–84) 66 (18–85) 0.89
Male sex 46 (66) 40 (73) 0.44
Surgical 36 (51) 26 (45) 0.47
Septicaemia 30 (43) 28 (51) 0.47
Pre-existing CRF 16 (23) 11 (20) 0.82
Oliguric 45 (64) 34 (62) 0.85
Mechanical ventilation 55 (76) 42 (77) 0.83
Catecholamine therapy 58 (80) 38 (70) 0.29
Aetiological factors for ARF
Ischaemic 41 (59) 32 (58) 0.91
Nephrotoxic 8 (11) 4 (7) 0.55
Multisystem disease 0 (0) 3 (5) 0.08
Unknown 21 (30) 16 (29) 0.87
Severity of illness scores
SAPS 55 (21–103) 55 (21–110) 0.67
Number of organs failing 3 (1–6) 3 (1–6) 0.64
Renal function markers
Urine output (ml/h) 9 (0–158) 10 (0–237) 0.14
Serum urea (mmol/l) 25.4 (8.7–39.9) 30.1 (6.3–57.6) 0.41
Serum creatinine (mmol/l) 342 (137–646) 335 (62–1037) 0.22
Values given are the number (%) or median (range).
Pre-existing chronic renal failure (CRF): serum creatinine
>150mmol/l at least 3 months before randomization.
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There were no between-group differences in the number
of patients receiving ﬂuids in the form of crystalloids
or blood and nutrition, either enteral or parenteral.
Patients in the IHD group received a slightly higher
amount of colloids. The rate at which these ﬂuids were
administered and the cumulative number of patient-
days administered was comparable in the two groups.
Vasopressor agents and hemodynamic stability
There was no difference in the number of patients or
the rate of adrenaline, noradrenaline or dopamine
used in the two groups (Table 4). Patients in the
CVVHDF group received on average slightly more
dobutamine than those on IHD (Table 4).
The average MAP for the ﬁrst 25 days from the
beginning of RRT in the two groups of patients is
reported in Figure 2. The incidence of circulatory
failure, as assessed by an average daily MAP
65mmHg throughout the entire ICU period, did not
differ between the CVVHDF (15 patients, 21%) and
IHD group (eight patients, 15%, P¼ 0.36). All these
patients were on vasopressor agents and there was
a 78% mortality among patients with circulatory
failure (CVVHDF vs IHD, 81 vs 71%, P¼ 0.62).
Haemodynamic instability, deﬁned as the average
variability between maximum and minimum daily
MAP, was also similar in CVVHDF (20 subjects,
29%) and IHD (22 subjects, 40%, P¼ 0.13) groups.
Quality of dialysis, control of azotaemia
and volume overload
Data on the quality of RRT was available from
121 patients, because 4 patients (3 in the CVVHDF
group and 1 in the IHD group) died after randomiza-
tion before RRT could be started. Mean blood ﬂow was
lower with CVVHDF than with IHD (159±18 vs
231±56ml/min, P<0.0001), while the average daily
duration of RRT was 20.5±6.2 h in the CVVHDF
group and 3.0±0.4 h in the IHD group (P<0.0001)
(Figure 3). Achieved urea clearances during RRT
Table 3. Fluids and nutrition in patients assigned to continuous
(CVVHDF) or intermittent (IHD) renal replacement therapy for
acute renal failure
Characteristics CVVHDF
(n¼ 70)
IHD (n¼ 55) P-value
Cumulative treatment
days
510 455
Fluids
Crystalloids
No. of patients (%) 70 (100) 55 (100) 1.00
No. of patient-days (%) 510 (100) 455 (100)
Volume (ml/12 h) 425 (20–4300) 425 (15–3080) 0.25
Colloids
No. of patients (%) 58 (83) 46 (84) 1.00
No. of patient-days (%) 163 (32) 150 (33)
Volume (ml/12 h) 500 (8–11200) 560 (50–3700) <0.01
Blood
No. of patients (%) 48 (69) 39 (71) 0.85
No. of patient-days (%) 96 (19) 78 (17)
Volume (ml/12 h) 300 (100–7150) 275 (100–2760) 0.83
Nutrition
Enteral
No. of patients (%) 69 (99) 54 (98) 1.00
No. of patient-days (%) 350 (68) 320 (70)
Volume (ml/12 h) 300 (17–1950) 340 (20–1400) 0.41
Parenteral
No. of patients (%) 40 (57) 36 (65) 0.36
No. of patient-days (%) 217 (42) 184 (41)
Volume (ml/12 h) 600 (21–1450) 650 (60–1700) 0.16
Values given are the number (%) or median (range).
Table 4. Catecholamines in patients assigned to continuous
(CVVHDF) or intermittent (IHD) renal replacement therapy for
acute renal failure
Characteristics CVVHDF
(n¼ 70)
IHD
(n¼ 55)
P-value
Cumulative treatment
days
510 455
Adrenaline
No. of patients (%) 31 (44) 15 (27) 0.06
No. of patient-days (%) 87 (17) 21 (5)
Dose (mg/12 h) 4070
(2–56 750)
7350
(2–80 500)
0.13
Noadrenaline
No. of patients (%) 38 (54) 28 (51) 0.72
No. of patient-days (%) 155 (30) 129 (28)
Dose (mg/12 h) 4300
(10–143 500)
3300
(47–161 350)
0.21
Dopamine
No. of patients (%) 5 (7) 7 (13) 0.37
No. of patient-days (%) 11 (2) 13 (3)
Dose (mg/12 h) 21 (2–156) 33 (1–485) 0.13
Dobutamine
No. of patients (%) 31 (44) 19 (35) 0.36
No. of patient-days (%) 150 (29) 76 (17)
Dose (mg/12 h) 32 (1–835) 24 (12–425) <0.001
Values given are the number (%) or median (range).
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averaged 30±4ml/min with CVVHDF and
198±39ml/min with IHD (P<0.0001). Thus, the
average daily small solute clearance was comparable
between the CVVHDF and IHD groups (25.9±5.9 vs
24.8±11.3ml/min, P¼ 0.34) (Figure 3). However,
the percentage of patients with an RRT clearance
>20ml/min was higher in the CVVHDF (84%)
than in the IHD group (57%, OR 3.9, P<0.001).
Mortality was similar in patients whose dose of RRT
was <20ml/min or 20ml/min (48 vs 46%, P¼ 0.89).
The amount of ﬂuid removed daily by RRT did not
differ between the two groups (CVVHDF 1170±1285
vs IHD 1307±1018ml/day). Average ﬂuid balance
was þ211±1351ml/12 h in CVVHDF patients and
þ230±1264 ml/12 h in IHD patients (P¼ 0.66). A
total of 97 (75%) patients were on assisted ventila-
tion during RRT [CVVHDF vs IHD, 55 (79%) vs
42 (76%), P¼ 0.98]. Ventilator-associated parameters
in the two groups were comparable, FiO2 was
48.7±19.4% in CVVHDF and 46.4±19.2% in IHD
patients (P¼ 0.09), and PEEP was 6.4±2.7mmHg
in CVVHDF and 6.4±2.5mmHg in IHD patients
(P¼ 0.87).
Duration of RRT and length of stay
Duration of RRT did not differ between CVVHDF
[6.0 (1–49) days] and IHD patients [7.0 (1–50) days,
P¼ 0.99]. There was no signiﬁcant difference in
the duration of RRT in the 64 survivors of the
CVVHDF [6.0 (1–38) days, n¼ 37] compared with
those in the IHD group [6.0 (1–49) days, n¼ 27,
P¼ 1.00]. The length of stay in the hospital was
calculated from the time of randomization. Hospital
length of stay did not differ signiﬁcantly between
CVVHDF and IHD survivors [20.5 (6–71) vs 30 (2–89)
days, P¼ 0.25].
Renal recovery
Of the 64 patients who survived, 62 (97%) had
complete or partial recovery of renal function.
One patient in each RRT group remained on dialysis.
The percentage of patients with full recovery of renal
function was 50% in the CVVHDF and 42% in the
IHD group (P¼ 0.61). Serum creatinine concentration
at hospital discharge was similar in patients random-
ized to CVVHDF [121 (72–242) mmol/l, n¼ 36] and
to IHD [153 (59–496) mmol/l, n¼ 26, P¼ 0.17] and was
not related to the presence of initial oliguria [non-
oliguric, n¼ 23, 142 (60–496) mmol/l vs oliguric, n¼ 39,
147 (59–443) mmol/l, P¼ 0.41] or the presence of
chronic renal insufﬁciency [non-CRF, n¼ 53, 125
(59–496) mmol/l vs CRF, n¼ 9, 208 (85–411) mmol/l,
P¼ 0.11]. Multiple regression analysis with type of
RRT, presence of pre-existing CRF, haemodynamic
stability, use of vasopressor agents and therapy with
aminoglycosides as independent variables revealed that
pre-existing CRF was an independent predictor of
renal recovery as measured by serum creatinine at
discharge (F-ratio 4.509, P¼ 0.038). In the 53 survivors
without pre-existing CRF, serum creatinine at
hospital discharge was 117 (72–242) mmol/l in the
CVVHDF group (n¼ 30) and 143 (59–496) mmol/l in
the IHD group (n¼ 23, P¼ 0.40).
Discussion
Since the introduction of continuous haemoﬁltration
and continuous haemodialysis, these techniques with
several modiﬁcations have turned out to be efﬁcient
and safe [1]. Despite the conceptual advantages of
continuous forms of RRT, including improved haemo-
dynamics, easier ﬂuid removal and ﬂexibility with
parenteral nutrition [1], continuous therapies exhibit
some potential drawbacks such as access-related
complications, bleeding and increased manpower or
ﬁnancial investments when highly sophisticated treat-
ment devices are used [1]. Whether these peculiar
features of the IHD and CVVHD methods are
relevant for the outcome of critically ill patients
with ARF can only be established in prospective
controlled studies. A large multicentre trial failed
30
25
20
15
10
5
0
A
ve
ra
ge
 d
ai
ly
 d
ur
at
io
n 
of
 R
RT
(h
)
300
250
200
150
100
50
0
Ur
ea
 c
le
ar
an
ce
 d
ur
in
g 
RR
T
(m
l/m
in)
35
30
25
20
15
10
5
0
A
ve
ra
ge
 d
ai
ly
 u
re
a 
cl
ea
ra
nc
e 
(m
l/m
in)
P<0.0001 
P<0.0001 
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to answer this question appropriately because of
inconsistencies in the randomization protocol [2].
Although the quality of RRT for patients with ARF
has improved steadily during the last decade, no
evidence with respect to survival rate suggests that
continuous RRT is superior to intermittent RRT [1].
The present investigation provides information from
a prospective, controlled trial about the effect of
the unrestricted application of either IHD or CVVHD
to all patients without any inclusion restrictions
related to the underlying disease entity or physician’s
preference, a design mimicking reality in many institu-
tions around the world where systematically either
an IHD or a continuous method for RRT is prescribed
in the ICU setting.
The worldwide standard care for ARF requiring
dialysis in the ICU is IHD, as recently mentioned by
Metha et al. [2]. Whereas this statement holds for many
institutions in the USA, it is not the case in other
countries such as, for instance, Australia, where
continuous RRT is applied to >97% of the patients
in the ICU by critical care physicians with restricted
input from nephrologists [6]. These differences in
physicians’ preferences in the therapeutic approach
for RRT in the ICU are by and large not evidence
based, only partly understood, and probably best
explained by local availability of devices for continuous
or intermittent treatment, reimbursement system,
training of physicians and their variable desire for
interdisciplinary work or adherence to recommenda-
tions given by their professional groups. Besides these
arguments accounting for the physicians’ preferences,
four aspects of potential beneﬁt for the patient would
argue in favour of the potentially more physiological
continuous RRT.
Haemodynamic stability. Haemodynamic instability
accounts for a substantial number of ICU patients
with ARF given primarily a continuous method of
RRT rather then IHD. In a recently published multi-
centre study, 21% were not randomized for haemo-
dynamic instability deﬁned as an MAP <70mmHg [2].
In the present investigation, patients were equally
randomized regardless of the initial haemodynamic
status. Moreover, the incidence of low blood pressure
(MAP 65mmHg) and the average variability between
maximum and minimum daily MAP throughout the
entire ICU period were similar in patients treated
with CVVHD and IHD, indicating no therapy-induced
enhanced instability. Patients treated with IHD
received slightly higher amounts of colloids. Since the
use of ﬂuids and nutrition was not controlled during
this study, we do not know if the higher amounts
of colloids administered during IHD were given to
counteract real or to prevent expected episodes of
haemodynamic instability.
In order to avoid or to enhance pre-existing
haemodynamic instability, the therapeutic maneouvre
of IHD was started gently with a blood ﬂow of
150ml/min, using a low surface area ﬁlter of 0.5m2
for a short duration of 2–3 h, removing small amounts
of ﬂuid (0–500ml/h). Such gentle procedures resulted
in daily IHD sessions for the majority of patients
during the ﬁrst days of RRT. The median frequency
of IHD sessions over the whole period of RRT was
ﬁve per week. The results would certainly have been
different if we had not chosen to let haemodynamic
stability guide our treatment prescriptions but rather
had tried to minimize the number of intermittent
treatments to three per week.
Removal of cytokines. It appears a priori reasonable
to remove continuously and not intermittently inﬂam-
matory mediators including cytokines in critically ill
patients with sepsis [7,8]. Mass-balance considerations
revealed, however, that only insigniﬁcant numbers of
these mediators are removed in comparison with
endogenous clearance [8,9]. Furthermore, it is
unknown whether the clearance of pro-inﬂammatory
endobiotics by the extracorporeal therapy is not
outweighed by a similar or even more pronounced
removal of their natural antagonists [8]. On the other
hand, dialysis procedures are pro-inﬂammatory by
themselves as a consequence of blood–membrane
contact [10–12]. Thus, it is conceivable that a shorter
duration of blood–membrane contact as in IHD might
diminish the overall exposure of the patients to
inﬂammatory mediators.
Total parenteral nutrition. Total parenteral nutrition
requires large amounts of ﬂuid dispensed daily, and in
patients with ARF can only be achieved when net ﬂuid
is removed. Therefore, one might anticipate a shorter
duration or lower dose of parenteral nutrition assigned
to patients on IHD than in those on CVVHD.
Interestingly, no such difference was found between
the two groups. This is best explained by the fact that in
our institution the need for nutrition and supplementa-
tion of blood constituents dictate the amount of dialysis
therapy delivered and not vice versa.
Delivered dose of dialysis. With increasing haemo-
dialysis, dose mortality rates decrease in chronic
haemodialysis patients in the out-patient environ-
ment [13,14] and in patients with ARF treated with
venovenous haemoﬁltration in the ICU [15,16]. Such a
dose–response relationship has been clearly observed
when the low dose range was considered for both
patients with CRF on IHD and patients with ARF on
venovenous haemoﬁltration or IHD. However, this
dose–response relationship has not been shown so far
in patients on chronic IHD [14] and was absent in
patients with ARF on venovenous haemoﬁltration [15],
when an intensive treatment strategy such as that for
both groups of patients in the present investigation
was applied. Thus, it appears that even when a high
dose of dialysis is delivered with IHD or CVVHDF to
patients with ARF in the ICU, their outcome with
respect to survival is not dependent on the type of
RRT chosen, provided an adequate dose of dialysis
is delivered which allows azotaemic control with full
nutritional support, volume, electrolyte and acid–base
balance [17]. These targets can only be reached of
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course with IHD when treatment sessions occur daily
whenever required [16].
The present study has limitations. The open design
which cannot be avoided for this type of therapeutic
interventions might have inﬂuenced the outcome of
the patients. The power of the study is lower than
originally predicted due to the pre-terminal end and
the smaller than expected number of patients included.
The studied number of 55 and 70 patients, respectively,
would only have allowed the detection of a mortality
difference of 25% between the two therapies with a
power of 80% [5]. The tendency for a slightly lower
mortality observed in the non-randomized patients
treated by IHD precludes a bias towards a healthier
patient population in the randomized patients treated
by IHD. More than two-thirds of the participants
were white men. Subgroup analyses were not possible
and thus it is conceivable that a potential beneﬁt of
CVVHDF might be present in other racial groups
or females, or patients with a speciﬁc disease state.
Furthermore, some patients with multiorgan failure
are so severely ill that they will die regardless of any
form of therapy delivered. Others are well enough to
survive any form of RRT. It is conceivable that the
observations at the two extremes of the severity of
illness spectrum have blunted any discrete advantages
of one over the other form of RRT.
The conclusion that IHD and continuous treat-
ment yield equal dialysis efﬁciency with respect to the
ﬁnal therapeutic end-point of survival is probably
only valid for institutions where for both treatment
modalities so-called biocompatible dialysis membranes
[18–20] and machines which allow accurate automated
volume/pressure control are applied by staff equally
trained to provide a tailored treatment for both
methods according to the patient’s need.
In summary, CVVHDF as compared with IHD
applied to medically unselected patients in a tertiary-
care university hospital does not reduce mortality,
nor does it inﬂuence length of stay, haemodynamic
instability or recovery of renal function.
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